Business Context and Reporting Period
Tenon Medical, Inc. (TNON), a Delaware corporation and emerging growth company, filed this Form 8-K on June 29, 2026, to report the entry into material definitive agreements. The filing details a best efforts public offering consummated on July 1, 2026, involving the sale of common stock, pre-funded warrants, and common stock purchase warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $4.2 million (before deducting placement agent fees and offering expenses).
- Offering Price: $0.38 per share (combined price for shares/pre-funded warrants and accompanying warrants).
- Securities Issued:
- 5,526,315 shares of Common Stock and/or Pre-Funded Warrants.
- Common Warrants to purchase up to 13,263,159 shares of Common Stock.
- Placement Agent Fees: 6.5% cash fee, 1% non-accountable expense allowance, and reimbursement of up to $65,000 in accountable expenses.
- Placement Agent Warrants: 331,579 warrants issued to WallachBeth Capital, LLC (3% of aggregate shares sold) with an exercise price of 120% of the public offering price.
Material Changes and Use of Proceeds
The filing does not provide comparative financial metrics (revenue, profit, cash flow, or margins) for the prior period as this is a current report on a specific transaction. The material change is the capital raise and the resulting dilution from the issuance of new shares and warrants.
Intended Use of Net Proceeds:
- Partial repayment of outstanding convertible notes.
- Expansion of commercial footprint, including clinician training and hiring direct sales representatives.
- Expansion of external distribution networks.
- Funding clinical research studies for reimbursement and coverage efforts.
- Research and development, including future product launches.
- Increases to inventory and instrumentation capacities.
- Marketing activities, working capital, and general corporate purposes.
Guidance, Restrictions, and Risks
- Lock-Up Agreements: Executive officers and directors are restricted from selling securities for 60 days following the closing of the offering.
- Issuance Restrictions: The Company is prohibited from issuing common stock or equivalents for 30 days post-closing (with exceptions) and from entering into variable rate transactions for 3 months post-closing.
- Warrant Terms: Common Warrants are immediately exercisable at $0.38 per share and expire on the 5th anniversary of the initial exercise date. Pre-Funded Warrants are exercisable at $0.001 per share.
- Beneficial Ownership Limits: Holders cannot exercise warrants to exceed 4.99% (or 9.99% with notice) of outstanding shares immediately after exercise.
- Reverse Stock Split Adjustment: If a reverse stock split occurs, the number of shares issuable under Common Warrants prior to the split will increase to 16,578,947.
Investor Verification Checklist
- Verify the net proceeds after deducting the 7.5% total cash fees and expense reimbursements to the placement agent.
- Confirm the exact amount of convertible notes to be repaid with the proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the Company's cash burn rate relative to the $4.2 million gross raise to assess runway extension.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants or changes in the capital structure.